I
Insilico Medicine
ListedAn AI-driven drug discovery company that uses deep learning for target identification, generative chemistry, and clinical trial prediction.
About
An AI-driven drug discovery company that uses deep learning for target identification, generative chemistry, and clinical trial prediction.
Detailed overview
PandaOmics is a generative AI software platform developed by Insilico Medicine for drug discovery and scientific research. It is designed for researchers and organizations involved in target identification, disease modeling, and therapeutic program development. The platform is part of Insilico Medicine’s broader Pharma.ai suite, which also includes Chemistry42 and Biology42 for generative chemistry and biology, as well as Science42:DORA and inClinico. PandaOmics supports capabilities such as target identification, hit-to-lead optimization, and IND-enabling studies, as indicated by its use across various stages of Insilico Medicine’s own therapeutic pipeline, including Phase II, Phase I, and discovery-stage programs. The platform is available for licensing and is intended to reduce the time and cost of bringing medications to patients by applying generative AI and automation to the drug development process. It is also described as contributing to longevity and sustainability research. The software is accessible through Insilico Medicine’s website, where users can request contact or download an overview.
Website link is available on the Verified plan